Does ranitidine cause gynaecomastia? This question has been raised by patients and clinicians alike, given that ranitidine — an H2-receptor antagonist once widely prescribed for acid-related conditions — was listed in archived SmPC and BNF data as having gynaecomastia as a rare post-marketing adverse effect. Although ranitidine is no longer available in the UK following MHRA and EMA action over NDMA contamination concerns, understanding its potential hormonal effects remains clinically relevant for those who previously took it and for broader awareness of drug-induced gynaecomastia.

Ranitidine and Gynaecomastia: What the Evidence Shows

Ranitidine is listed as a rare post-marketing cause of gynaecomastia, but evidence is based on case reports and pharmacovigilance data rather than controlled trials, and any anti-androgenic effect is minimal and uncertain.

Ranitidine is an H2-receptor antagonist (H2 blocker) that was widely used to reduce stomach acid in conditions such as gastro-oesophageal reflux disease (GORD), peptic ulcers, and indigestion. It works by selectively blocking histamine H2 receptors on the parietal cells of the stomach lining, thereby reducing acid secretion. From 2019 onwards, the MHRA issued product recalls of ranitidine medicines in the UK, and the EMA recommended suspension of ranitidine-containing medicines across the EU, following concerns about contamination with N-nitrosodimethylamine (NDMA), a probable human carcinogen. As a result, ranitidine is no longer available for prescription or over-the-counter use in the UK.

Regarding gynaecomastia — the benign enlargement of glandular breast tissue in males — there is a limited body of evidence suggesting a possible association with ranitidine use. Archived SmPC data and BNF monographs have listed gynaecomastia as a post-marketing adverse effect of ranitidine, with a frequency categorised as rare or frequency not known. The proposed mechanism has historically drawn on comparisons with cimetidine, a closely related H2 blocker with well-established anti-androgenic properties that can interfere with androgen receptor binding and disrupt the balance between oestrogen and testosterone. However, ranitidine's endocrine effects are considerably less clear and are not well supported by robust pharmacological evidence; any anti-androgenic activity, if present at all, is likely to be minimal and uncertain.

It is important to note that there is no definitive, large-scale clinical trial confirming a direct causal link between ranitidine and gynaecomastia. The association is based on post-marketing case reports and pharmacovigilance data rather than controlled studies. Clinicians and patients should therefore interpret this relationship with appropriate caution.

How Common Is This Side Effect and Who Is Most at Risk

Gynaecomastia from ranitidine is categorised as rare (fewer than 1 in 1,000) or frequency not known; older men, those with hormonal imbalances, and those on multiple hormonal medicines are most vulnerable.

The precise incidence of gynaecomastia as a side effect of ranitidine is not established. Archived SmPC and BNF sources categorise it as rare (affecting fewer than 1 in 1,000 people) or as frequency not known, reflecting the limitations of post-marketing surveillance data. It is not a predictable or common consequence of treatment, and it is considerably less frequently reported than with cimetidine, which has a stronger and better-characterised hormonal effect.

Certain groups may be more vulnerable to developing drug-induced gynaecomastia:

• Older men, in whom baseline testosterone levels are naturally declining, may be more susceptible to any additional hormonal disruption.

• Individuals with pre-existing hormonal imbalances, such as hypogonadism or liver disease (which affects oestrogen metabolism), may face a higher risk.

• Those taking multiple medicines with hormonal effects simultaneously, as the cumulative impact on the oestrogen-to-testosterone ratio may be greater.

In documented cases, gynaecomastia associated with ranitidine has generally been reversible following discontinuation of the drug, though improvement may take several months. It is worth noting that longstanding gynaecomastia with fibrotic tissue changes may be less fully reversible. Given that ranitidine is no longer available in the UK, this is now largely of historical and academic interest. Patients who previously experienced this side effect and are concerned about persistent breast tissue changes should seek medical review, as other underlying causes must be excluded.

Other Medicines and Causes of Gynaecomastia to Consider

Many medicines cause gynaecomastia, including spironolactone, cimetidine, anti-androgens, and anabolic steroids; non-drug causes such as hypogonadism, liver disease, and testicular tumours must also be excluded.

Gynaecomastia is a multifactorial condition, and it is essential not to attribute breast tissue enlargement in males solely to any single medication without thorough clinical assessment. A wide range of medicines are known to cause or contribute to gynaecomastia through various mechanisms, including anti-androgenic effects, increased oestrogen activity, or disruption of the hypothalamic-pituitary-gonadal axis. Commonly implicated drug classes include:

• Spironolactone — a potassium-sparing diuretic with well-documented anti-androgenic properties

• Cimetidine — an H2 blocker with a well-established stronger hormonal effect than ranitidine

• Anabolic steroids and testosterone therapy — paradoxically, exogenous androgens can convert to oestrogens via aromatisation

• Anti-androgens (e.g., bicalutamide, cyproterone acetate, finasteride, dutasteride) — used in prostate cancer treatment or androgenic conditions

• GnRH analogues (e.g., goserelin, leuprorelin) — used in prostate cancer and other conditions

• Some antipsychotics and antidepressants — which can elevate prolactin levels

• Digoxin — which has oestrogen-like activity

• Ketoconazole — which inhibits androgen synthesis

• Verapamil and certain other calcium-channel blockers

• Opioids — associated with hypogonadism and hormonal disruption

• Certain antiretrovirals (e.g., efavirenz)

• Oestrogens and oestrogen-containing preparations

• Proton pump inhibitors (PPIs) — occasionally mentioned in case reports, though causality is uncertain and evidence is very limited

Beyond medications, gynaecomastia has numerous non-drug causes that must be considered. Physiological gynaecomastia occurs naturally during puberty and in older age due to hormonal shifts. Pathological causes include hypogonadism, hyperthyroidism, chronic liver disease, renal failure, and — importantly — testicular or adrenal tumours, which can produce excess oestrogen or human chorionic gonadotrophin (hCG). Obesity can also cause pseudo-gynaecomastia (fatty tissue rather than true glandular enlargement) and increases peripheral aromatisation of androgens to oestrogens.

Clinical assessment of gynaecomastia typically involves a thorough medication review, hormonal blood tests (LH, FSH, testosterone, oestradiol, prolactin, hCG, and thyroid function), and basic biochemistry including liver function tests (LFTs) and renal function. Testicular ultrasound should be considered where clinical examination is abnormal or hCG is raised. Breast imaging may be warranted where clinical features are suspicious. Where features suggest possible malignancy, referral under the NICE NG12 suspected cancer pathway should be considered (see below).

When to Speak to a GP or Pharmacist

Anyone noticing unexplained breast enlargement, a firm lump, nipple discharge, or skin changes should seek prompt GP review to exclude male breast cancer and other serious conditions.

Anyone who notices unexplained breast tissue enlargement, breast tenderness, or a palpable lump in the chest area should seek prompt medical advice. Whilst gynaecomastia is often benign, it is important to rule out serious conditions — including male breast cancer, which, although rare, can present similarly. A GP will typically take a full medical and medication history, perform a physical examination, and arrange appropriate investigations.

You should contact your GP promptly if you notice:

• A new, firm, or rapidly growing lump in one or both breasts

• Breast pain or tenderness that is persistent or worsening

• Nipple discharge, skin changes, or nipple inversion

• Breast changes accompanied by other symptoms such as unexplained weight loss, fatigue, or testicular changes

In line with NICE NG12 (Suspected Cancer: Recognition and Referral), GPs should consider an urgent two-week-wait referral for men aged 50 and over with an unexplained unilateral, firm subareolar mass, with or without nipple changes or discharge, to exclude male breast cancer.

If you are currently taking a medicine you suspect may be contributing to gynaecomastia, do not stop taking it without first speaking to your GP or pharmacist. Abruptly discontinuing certain medicines — particularly those for heart conditions, mental health, or hormonal therapies — can carry significant risks. A healthcare professional can review your medication regimen, consider switching to an alternative with a lower hormonal risk profile, and monitor for resolution of symptoms.

Pharmacists are also an accessible first point of contact and can advise on whether a current or recently taken medicine is associated with gynaecomastia, and whether a GP referral is warranted. Patients previously prescribed ranitidine are usually switched to alternatives such as omeprazole or lansoprazole (PPIs) or famotidine (an H2 blocker) as clinically appropriate; your GP or pharmacist can advise on the most suitable option for your individual circumstances.

If you believe you have experienced a side effect from any medicine, you can report it directly to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk. Reporting suspected adverse reactions helps improve the safety information available for all medicines.

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions